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Only a few studies have addressed the cost-effectiveness of pharmacogenetics 
interventions in healthcare. Lack of health economics data on aspects of pharmacogenetics 
is perceived as one of the barriers hindering its implementation for improving drug safety. 
Thus, a recent Institute for Prospective Technological Studies (IPTS) study, entitled 
‘Pharmacogenetics and pharmacogenomics: State-of-the-art and potential socio-economic 
impact in the EU’ included an explorative cost-effectiveness review for a pharmacogenetic 
treatment strategy compared with traditional medical practice. The selected case study 
examined the cost-effectiveness of thiopurine methyltransferase (TMPT) genotyping prior 
to thiopurine treatment in children with acute lymphoblastic leukemia (ALL). Information 
for the cost-effectiveness model parameters was collected from literature surveys and 
interviews with experts from four European countries (Germany, Ireland, the Netherlands 
and the UK). The model has established that TPMT testing in ALL patients has a favorable 
cost-effectiveness ratio. This conclusion was based on parameters collected for TPMT 
genotyping costs, estimates for frequency of TMPT deficiency, rates of thiopurine-
mediated myelosuppression in TPMT-deficient individuals, and myelosuppression-related 
hospitalization costs in each of the four countries studied. The mean calculated cost per 
life-year gained by TPMT genotyping in ALL patients in the four study countries was €2100 
(or €4800 after 3% discount) based on genotyping costs of €150 per patient. Cost per life-
year gained is expected to further improve following the introduction of the wider use of 
TMPT genotyping and the availability of lower cost genotyping methods. Our analysis 
indicates that TPMT genotyping should be seriously considered as an integral part of 
healthcare prior to the initiation of therapy with thiopurine drugs.uthAdvances in pharmacogenetics and pharmaco-genomics (collectively termed PGx) could posi-tively impact the pharmaceutical and healthcaresectors facilitating drug development and a sys-tem of medical care where drugs could be used in
a safer and more effective manner. However,
many expectations surrounding the clinical
application of PGx remain unfulfilled due to
several barriers, including:
• The slow development of the evidence base
for genotype-phenotype correlations for many
genes related to drug pharmacokinetics and
pharmacodynamics
• A lack of physician awareness and education
in molecular genetics and PGx
• A lack of incentives to facilitate the develop-
ment of PGx diagnostics for drugs that have
already been licensed [1–4]
Only a limited number of PGx applications have
reached clinical practice. The potential impact of
PGx on healthcare quality and its socio-economic
implications are still uncertain. Clarifying the eco-
nomic aspects of using pharmacogenomic knowl-
edge in drug treatment strategies may facilitate
their implementation. Other topics, such as ethi-
cal and legal aspects, have to be studied in addi-
tion, before a well-considered decision about
implementation can be made [5–7]. However eco-
nomic considerations are likely to play a key role
as resources for improving healthcare are limited
and must be decided upon in a prudent manner.
With the aim of gaining knowledge on global
trends in PGx translational research in academia
and the private sector, and diminishing some of
these socio-economic uncertainties, the Institute
for Prospective Technological Studies (IPTS) [101]
of the European Commission Joint Research
Centre (JRC) has recently completed a prospec-
tive study of the PGx field, entitled ‘Pharmacoge-
netics and pharmacogenomics: State-of-the-art
and potential socio-economic impact in the
EU’ [8,102]. Notably, few studies into the















undertaken. A recent systematic review of cost-
effectiveness analyses of pharmacogenomic inter-
ventions in the medical literature published by
Phillips and Van Bebber [9] identified only 11
studies that met the inclusion criteria for a cost-
effectiveness analysis, with most of these being
performed in the USA. A PubMed search carried
out in April 2006, based on the criteria of Phillips
and Van Bebber, resulted in only one additional
cost-effectiveness analysis published since 2004
[10]. One of the aims of the IPTS study was there-
fore to undertake cost-effectiveness studies for
PGx in the European clinical setting, which has
distinct features when compared with USA
healthcare, and to assess the feasibility of incorpo-
rating PGx diagnostic tests into European health-
care systems. In order to provide wide-ranging
conclusions for policy makers, these case studies
were performed in parallel in four EU member
states: Germany, Ireland, the Netherlands and the
UK. Other aspects of the study, including market
size, reimbursement, quality assurance and pro-
fessional education related to TPMT testing, as
well as additional societal, legal, and regulatory
and licensing considerations of PGx products in
general, are included in the study report available
on the IPTS web site [102]. 
Thiopurine drugs & TPMT phenotype & 
genotype measurements
Acute lymphoblastic leukemia (ALL) is the most
common malignancy of childhood, accounting for
approximately 78% of all childhood cancers, with
a reported annual incidence rate in the UK of
30–35 per 1 million among children aged 0–14
years, and showing a recent trend for a 0.7%
annual increase in incidence [11]. Most of these
children are treated with thiopurine drugs which
have helped to dramatically improved the ALL
cure rate [12]. In 1953, the purine drug 6-mercap-
topurine (6-MP) was launched in the USA, and
soon thereafter in Europe, under the brand name
Purinethol®. The drug inhibits DNA synthesis by
blocking the production of guanosine, and thus
has therapeutic applications in the treatment of
cancer and autoimmune diseases. The expectations
of 6-MP were high, and indeed it proved effective
in curing many children of leukemia. However,
soon thereafter researchers discovered that the drug
could be extremely toxic for some patients due to
severe myelosuppression [13]. The same scenario
occurred with another thiopurine drug, azo-
thioprine, marketed in Europe and the USA since
1968 as Imuran®, where toxicity and fatal sepsis
were reported in transplant patients [14].
In the 1990s it became evident that such toxic
reactions to thiopurine drugs involve an inher-
ited deficiency in the enzyme thiopurine methyl
transferase (TMPT), the key catabolic enzyme of
thiopurines [15–18]. Polymorphisms in the TPMT
gene are responsible for large interindividual dif-
ferences observed in the activity of the TPMT
enzyme. Individuals with two defective copies of
the TPMT gene – approximately 0.3% of Cau-
casians – are at increased risk of thiopurine-
induced toxicity [19,20]. Evidence was also
obtained that approximately 10% of patients
have intermediate TPMT activities, representing
a heterozygous deficiency, in whom severe toxic-
ity was less likely, but who were also at increased
risk of myelosuppression rom standard doses of
thiopurine drugs [20].
Thus, it is prudent to identify a patient’s
TPMT activity level before starting therapy, and
chose lower thiopurine dosage or alternative drug
for patients with intermediate TPMT levels or
deficient metabolizers. Phenotypic TPMT assays,
performed using the patient's red blood cells as
the source of the enzyme, have also been devel-
oped [21]. However, the phenotypic assay is labor-
intensive, requires qualified knowledge and
expensive instrumentation, and is impractical in
patients receiving blood transfusions [22].
Genotype assays for TPMT may circumvent
some or all of these drawbacks, and comparative
studies of genotyping and phenotyping for
TPMT testing are underway. The basic molecular
genetic testing methodology developed in the mid
1990s for the detection of mutations associated
with TPMT deficiency utilizes polymerase chain
reaction (PCR) combined with restriction enzyme
digests to detect the presence or absence of specific
DNA sequences at a known loci [16]. However, as
patents for thiopurine drugs are long since
expired, there has been little commercial interest
from pharmaceutical companies to develop tests
for identifying TPMT-deficient individuals who
are at increased risk of suffering myelosuppres-
sion. In the 1990s, commercial DNA tests to pre-
dict thiopurine drug toxicity became available in
the USA. Several companies (for example, Pro-
metheus Laboratories, CA, USA [103]) have devel-
oped tests for TPMT genotype or phenotype
screening which they offer as a service. 
Cost-effectiveness analysis of using 
pharmacogenomics in clinical practice
Analyzing the cost-effectiveness of a PGx strat-
egy in healthcare involves the comparison of the















conventional clinical practice of not using PGx
information for pharmacotherapy decisions.
When drug safety issues related to polymorphic
drug-metabolizing enzymes (DMEs) are consid-
ered, key factors in the cost-effectiveness com-
parison include the polymorphic genotypes of
interest and their incidence in the relevant popu-
lation, the genomic test, the disease state, the
treatment and its potential adverse drug reac-
tions (ADRs). A PGx-based treatment strategy is
likely to be more cost-effective when:
• The relevant genetic polymorphism is preva-
lent in the population and has a high degree of
penetrance (that is, being highly correlated
with a corresponding phenotype)
• The available genetic test is highly sensitive,
specific and inexpensive
• The disease state involves outcomes with signif-
icant morbidity or mortality if left untreated
• The pharmacotherapy involves a drug with a
narrow therapeutic index, and therefore sig-
nificant and costly ADRs that can be avoided
to a significant degree by genotype-individual-
ized therapy [23]. 
Cost-effectiveness analysis is a widely-used tool
to assess the value of new healthcare interven-
tions. Only a few published articles introduce
this kind of analysis to the field of pharmaco-
genomics (for example, [24–29]). 
Studies on the cost-effectiveness of TPMT gen-
otyping have concentrated on azathioprine treat-
ment in adults [27–29]. All these studies favor the
introduction of PCR testing to identify TPMT
polymorphisms prior to azathioprine treatment.
In the present study, the cost-effectiveness of the
use of TPMT testing in combination with treat-
ment with 6-MP in children with ALL is
explored. Cost-effectiveness analyses reported in
the scientific literature very seldom include com-
parisons across different countries. In the present
study, information for costs of treating thiopu-
rine-related ADRs, costs of TPMT genotyping,
and other parameters were collected from experts
in four European countries: Germany, Ireland, the
Netherlands, and the UK. 
Data collection & analysis 
A model was developed for the comparison of the
costs and effects of the TPMT genotyping-based
thiopurine treatment strategy in ALL as compared
with the traditional medical practice without
TPMT genotyping, and the model parameters
were identified. The model parameters concern
economic, genetic and clinical data. Information
on model parameters was collected from literature
and from expert opinions in the different partici-
pating countries (Germany, Ireland, the Nether-
lands and the UK). In general, not much
information on the parameters for the TPMT
model was specifically available for children with
ALL. Therefore, estimates from pharmacoeco-
nomic studies on other thiopurine drugs are fre-
quently used [27–29]. Further details on expert
interviews and literature searches are available in
the recently published IPTS report [102].
The analyses were performed from the societal
perspective, meaning that all medical costs and
effects are included regardless of who incurs the
costs and who obtains the effects [25]. Indirect
costs were not included, such as lost working
time for parents of children with ALL in cases of
ADRs necessitating hospitalization or additional
clinic visits. Costs are shown in 2004 Euros (€).
When costs were from other years, the effect of
price inflation was removed by using the harmo-
nized annual average price indices of the differ-
ent case study countries to inflate the data to the
year 2004.
In the calculation of the cost-effectiveness
ratios, both costs and effects were discounted at a
rate of 3% to convert future costs and health
effects to their present value (i.e., US dollars
expended or health effects experienced n years in
the future are discounted at a factor of
1/[1.03]n), as recommended by the Panel on
Cost Effectiveness in Health and Medicine [30].
TPMT activity in the general population
The distribution of TPMT activity in the popula-
tion differs with respect to ethnicity. For this study
we used the distribution as found in Caucasians.
The majority of the individuals (approximately
89%) have high TPMT activity, corresponding to
the homozygous wild-type genotype. Approxi-
mately 11% of the population are heterozygote at
the TPMT gene locus and have intermediate
TPMT activity. Homozygotes with two TPMT
mutant alleles have deficient TPMT activity and
account for 0.3% of the Caucasian population
[16]. Similar levels of TPMT deficiency were
reported in Asian [31] and African populations [32],
although in some African populations TPMT
deficiency might be slightly more frequent c
ompared with Caucasians [32].
Adverse events
Myelosuppression (leucopenia) is the most severe
and life-threatening ADR associated with thiop-















suppression is still associated with prolonged
hospitalizations and with patient suffering.
Sanderson and colleagues reported a frequency
of myelosuppression of between 1.4–5% of thi-
opurine-treated patients [33]. Winter and col-
leagues [28] assumed the frequency of leucopenia
in adults with inflammatory bowel disease
treated with thiopurine drugs to be 3.2%, based
on the results of seven studies. For patients with
rheumatological conditions treated with azathio-
prine, Marra and colleagues [27] assumed a higher
probability of hematological cytopenia of 9%.
Other adverse events include allergic reactions
(2.3%), nausea, vomiting, lack of appetite,
diarrhea (1.4–5%), pancreatitis (1.4–5%), and
infections (7%). These adverse events were not
included in the analysis, as their costs are
assumed to be minor by comparison. Thus, for
the current analysis we considered only medical
costs related to myelosuppression, and employed
the more conservative base value of 3% as proba-
bility of myelosuppression in thiopurine-treated
individuals based on the studies of Winter and
colleagues [28] and Sanderson and colleagues [33]. 
However, prospective evaluation of TPMT
activity or gene status will not eliminate all cases
of myelosuppression. Marra and colleagues [27]
assumed that approximately 50% of the cases of
hematological toxicity could be eliminated by
screening for TPMT and dosage reduction.
Sanderson and colleagues [33] suggest 29% of the
adverse reactions to be the result of overdosing
6-MP, based on the study of Colombel and col-
leagues [34]. Based on the studies [34–36] cited by
Winter and colleagues [28], they assume an asso-
ciation of leucopenia with TPMT deficiency of
32%. That is, only one in three cases of myelo-
suppression during thiopurine therapy is likely
to be the result TPMT deficiency. The latter
value was therefore used as base value for the
analysis, and a conservative value of 20% and the
value of 50% used by Marra and colleagues [27]
were used for the sensitivity analysis.
Myelosuppression may lead to death. Winter
and colleagues [28] assumed that in case of TPMT
screening of 1000 patients treated with a thiopu-
rine drug, one death may be avoided. We have
used this as our base value. As no data exists to
support this assumption, we varied this assump-
tion in our sensitivity analysis considerably from
a conservative assumption of one death avoided
in 10,000 patients to the assumption of avoiding
three deaths per 1000 patients. There is a strong
trend of improved life expectancy for children
with ALL [37]. The difference of the life expect-
ancy of children with ALL with the average EU
life expectancy even seems to be closing. In this
study we assumed the average EU life expectancy
of 75 years for children with ALL. In the sensi-
tivity analysis a life expectancy of 64 years is used
as found by Viscomi and colleagues for the
period 1987–1991 [37]. Using our base case
assumption of avoiding one death in case of
TPMT screening of 1000 patients and a mean
life expectancy of 75 years indicates that when
we perform our analysis for children that are on
average 8 years old, screening of 1000 patients
will result in 67 life years gained, or with a dis-
count of 3%, 29.6 life-years gained.
PCR test sensitivity & specificity
Oh and colleagues [29] assumed the sensitivity
and specificity of PCR genotyping for TPMT
type *2, *3A, *3B and *3C, to be 96.3 and
100%, respectively. Marra and colleagues [27]
used slightly different estimates for the sensitiv-
ity and specificity of the PCR genotyping for
type *2 and *3A, of 95.2 and 100%, respectively.
We conservatively used 95.2% as our base value
for the sensitivity. 
TPMT genotyping costs
Large differences were found in the costs of the
PCR test, consisting of the material and person-
nel cost of performing the PCR test, reported by
the different countries. Experts in the UK
reported an amount of £20–30 (€29–44). In
Germany, a wide range from €32–300 was
reported. For the Netherlands, the cost of PCR
testing were taken to be €175, based on national
tariffs. In Ireland, experts estimated the cost per
test as €250. In previous cost-effectiveness analy-
ses, amounts of CAD$100 (€72 price level 2004,
[27]) and £30 (€44 price level 2004, [28]) were
reported for TMPT genotyping. We have used
the PCR cost of €150 as base value, and the val-
ues of €30 and €300 as lower and upper cost val-
ues, respectively, for the sensitivity analysis.
Costs of adverse events
The costs of adverse events were based on hospital
days and outpatient visits, as other medical costs
are minor by comparison. A Dutch expert esti-
mated that 10% of the patients with a serious
ADR require in-patient treatment for at least
7 days. In the Netherlands, this amounts to
€2549, price level 2004 [38]. According to this esti-
mate, the other 90% of the patients having serious
ADRs are managed as out-patients. As they already















mated that this will not result in additional costs.
The average healthcare cost per patient with an
adverse reaction to thiopurine drug treatment for
the Dutch situation can thus be estimated at €255.
Winter and colleagues [28] assumed that in the
UK, two-thirds of patients suffering significant
leucopenia could be managed as out-patients,
requiring two additional visits at £115 (€168).
The remaining patients would require hospital
admission due to infective complications.
Assuming them to stay for 10 days in a hematol-
ogy ward at £402/day, results in a total amount
of £4020 (€5863) for these patients. The average
cost per patient in the UK can thus be calculated
to be €2178. 
Tavadia and colleagues [26] reported Canadian
costs of adverse events of CAD$7757 (€5578) per
case. Marra and colleagues [27] assumed that 50%
of the patients with adverse events would need to
be hospitalized, for an average duration of 10 days
amounting to CAD$ 2679 (€1925). For the 50%
of the patients able to be managed as outpatients
the costs were assumed to be CAD$ 790 (€568).
The average cost per patient amount was €1247.
The interim value of €1000 per myelosuppression
event was therefore used on the cost-effectiveness
analysis (Table 1), and the range of €250–2200
(Table 2) was used for the sensitivity analysis. 
Base case analysis
Table 1 presents the base values of the model
parameters used in the case model. The values
are based on the values for the parameters found
in literature and reported by experts as described
above. The base case values are in between the
range described for a model parameter.
Sensitivity analysis
In the sensitivity analysis the values of the model
parameters are varied, in order to determine the
degree of influence each parameter has on cost-
effectiveness. The lower and upper values are
based on the values for the parameters found in
the literature and reported by experts as
described above (Table 1).
Results
Base case analysis
The cost-effectiveness analysis was performed for
a hypothetical cohort of 100,000 children with
ALL using the base case values shown in Table 1.
Of these 100,000 children, 3000 will experience
myelosuppression, of which 960 cases are
directly related to TPMT deficiency. Assuming a
sensitivity of the PCR test of 95.2% indicates
that 914 of the 960 ADRs directly due to TPMT
deficiency may be prevented by screening for
TPMT prior to initiation of 6-MP treatment.
The cost of PCR tests for 100,000 children
with ALL, using the mean cost of €150 per test,
amount to €15 million. The direct healthcare
cost savings due to the prevention of hospitaliza-
tions of 914 ALL children with adverse events,
when using the base values from Table 1, amount
to approximately €932,000. 
However, the costs saved by prevention of
ADR-associated hospitalizations following thi-
opurine therapy in children with ALL are a
minor consideration compared with the poten-
tial for saving lives. If we were to avoid one death
per 1000 children screened, as explained above,
we save 100 children from this hypothetical
cohort, that is, we save 6700 life-years by screen-
ing 100,000 children. Since screening the cohort
for TMPT genotypes costs €15 million, follow-
ing deduction of the costs saved for hospitaliza-
tions it would cost €14,068,000 to save these
100 children from the hypothetical cohort.
Thus, assuming a life expectancy of 67 addi-
tional years per 8-year old child saved, it would
cost €2100 per life-year gained, or €4800 after
3% discounting. 
Sensitivity analysis
For a univariate sensitivity analysis we varied
one variable at a time (Table 2). Using the lower
values for each of the variables, probability of
myelosuppression, adverse events associated
with TPMT, mortality prevented per person
screened for TPMT, life expectancy for children
with ALL, sensitivity of the PCR test and the
costs of myelosuppression leads to slightly
higher costs per life-year gained, hence less favo-
rable cost-effectiveness ratios. However, the
changes in the cost-effectiveness ratio when
changing most parameters were very small.
Only when changing the value of mortality pre-
vented per person screened for TPMT, from one
in 1000 to one in 10,000s, did the costs per life-
year gained increase considerably, to €47,600.
In contrast with the other parameters, lowering
the costs of the PCR test to the minimum value
of €30 (Table 1), leads to a more favorable cost-
effectiveness ratio of €700 per life-year saved.
Using the upper values of the parameters had
the opposite effect.
In a multivariate sensitivity analyses, we varied
all model parameters included in the sensitivity
analysis (Table 2) together to arrive at the best and















gained). Under the assumption that all of the
model parameters mentioned in Table 2 are inde-
pendent from each other, we can construct a set of
extreme parameter values that yield the highest
and the lowest cost-effectiveness ratios. To con-
struct the highest (least favorable) cost-effective-
ness ratio, we took the lower values for the
probability of myelosuppression, the percentage
of adverse events directly associated with TPMT
deficiency, the mortality prevented by TPMT
screening and the costs of myelosuppression. For
the costs of the PCR test, we used the upper value.
This resulted in a cost-effectiveness ratio of
€53,500 per life-year saved (€107,900 per life-
year gained, with 3% discounting). In contrast,
for the lowest (most favorable) cost-effectiveness
ratio, taking the upper values for the probability
of myelosuppression, the percentage of adverse
events directly associated with TPMT deficiency,
the mortality prevented by TPMT screening and
the costs of myelosuppression, and taking the
lower value for the costs of the PCR test, resulted
in both financial savings (€6.4 million) and a gain
in life-years (8900 years, 3% discounting) for a
cohort of 100,000 children. 
Discussion
The current cost-effectiveness analysis shows
that screening for TPMT genotypes in children
with ALL prior to treatment with thiopurine
drugs is highly cost-effective, and thus desired
from the socio-economic perspective. This is evi-
dent from the cost-effectiveness ratio, defined as
the cost per life-year gained, which was calcu-
lated as only €2100 (or €4800 after 3% dis-
count) using the base value estimates collected
from experts and literature surveys for the four
European countries included in the study. This
value is by far smaller than the value of US$
50,000 per life-year gained – often used as a
threshold value for indicating a very favorable
outcome of cost-effectiveness studies in the USA
and £30,000 per quality-adjusted life year
(QALY) gained, which is the UK threshold set
up by the National Institute for Clinical Excel-
lence (NICE) [104]. It is worth mentioning that
there is no agreed European threshold for con-
sidering a new technology or treatment as cost-
effective. Given that our case studies are set in
the UK, Germany, the Netherlands and Ireland,
we have reviewed the healthcare technology
assessment guidelines for the four mentioned
countries. It should be highlighted that only the
UK, NICE, sets up the criteria of acceptability
for a technology as cost-effective [104]. Thus, an
examined medical procedure is typically consid-
ered to be cost-effective for society as long as the
cost per life-year gained by the procedure
remains below this threshold.
Univariate sensitivity analysis was performed by
changing each of the base values shown in Table 2
to less or more favorable ones. As shown in Table 2,
in most cases this leads to only minimal effect on
the calculated cost-effectiveness ratios. Only when
the value of mortality prevented per person
screened for TPMT is changed from the base value
of one in 1000 patients to one in 10,000 patients,
the costs per life year gained increased considerably
Table 1. Base case value parameters TPMT model, and lower and upper values for 
parameters included in the sensitivity analysis. 





Probability of myelosuppression 0.03 0.01 0.1
Adverse events associated with TPMT 32% 20% 50%
Mortality prevented per person screened for TPMT 0.001 0.0001 0.003
Life expectancy 75 years 64 years‡
Sensitivity PCR test 95.2% 76.2%* 99.9%*
Specificity PCR test 100%
Costs PCR test (€ price level 2004) 150 30 300
Costs of myelosuppression (€ price level 2004) 1000 250 2200
‡Based on Viscomi and colleagues [37], assuming 50% boys and 50% girls.
*Marra and colleagues [27].















to €47,600. However even this high value is still
within the range typically considered as cost-effec-
tive. Only the outcome of €101,200 per life-year
gained, obtained by constructing a set of extreme
parameter values that yield the least favorable cost-
effectiveness ratio, appears well above what would
have been deemed cost-effective. Only in robust
cases, the NICE criteria would accept this figure as
“above an incremental cost effectiveness ratio of
£30,000/QALY, the case for supporting the tech-
nology on these factors has to be increasingly
strong” [104]. It could be argued that saving chil-
dren's' lives by avoiding thiopurine-mediated mye-
losuppression does make a strong enough case for
TPMT genotyping. In any case, the most favora-
ble cost-effectiveness ratio resulted in both finan-
cial savings and a gain in life-years due to TPMT
screening. To narrow the uncertainty, further
research on the model parameters is warranted.
Preferably, the probability of dying due to myelo-
suppression should be assessed, based on primary
data collection. With help of this information the
model structure and outcomes can be optimized.
A base value of €150 was employed here for
TPMT PCR genotyping costs. However, there
was a large range of estimates for costs of PCR
assays, for example in the range of €32–300 for
Germany. This may be caused, in part, by the
number of different genotypes assessed. Some
centers assay only the most common TPMT
mutations whereas others perform a “genome
scan” which is more expensive but allows a
higher sensitivity. Using the low value of €30 for
the analysis leads to a fivefold reduction in the
cost of life-year gained to only €705 (after 3%
discount). In this context, it is important to keep
in mind that genotyping costs are expected to
decline in the future [39]. 
The reported costs of adverse advents also
varied between the countries participating in
this study. This may be due to real cost differ-
ences caused by different prices of healthcare
services and products between countries, differ-
ences in protocols for treatment of the adverse
advents, or incomplete estimates of experts.
However, the sensitivity analysis showed that
these costs have minor consequences for the
cost-effectiveness ratio. Of note, the same con-
siderations for better cost-effectiveness of PGx
data for reduced genotyping costs may be true
for other PGx tests capable of improving drug
safety and/or efficacy. At any rate, genotyping
costs for each of the drug-metabolizing enzymes
(DMEs) tested might be substantially reduced if
tests for many DMEs were to be combined in a
single DNA-based chip examining them in par-
allel. Obtaining the full cost-effectiveness
advantage from such chip-based multi-DME
screening (or DNA sequencing) strategies
would require the setting up of reliable elec-
tronic-health (e-health) technologies, so that
the data gained from a once in a lifetime geno-
typing would be available for treating physicians
(and only to them) throughout the individual's
life, possibly even in cases where the health pro-
vider and/or country of residence are changed.
However, this would require solving crucial eth-
ical and privacy concerns and setting up inter-
national agreements for e-health data storage
and transfer. Hopefully such barriers would
soon be solved, so that the potential of pharma-
cogenomics, highly related to the consistent
nature of genomic data, can be harnessed for
improving healthcare quality and equality.
When comparing cost-effectiveness of TPMT
genotyping for pediatric ALL patients in the four
case study countries, variables that may affect
Table 2. Univariate sensitivity analysis: cost-effectiveness ratio, expressed as costs in 
EUR (price level 2004) per life-year gained (3% discounting).
Model parameter* Lower value Upper value
Probability of myelosuppression 5000 4000
Adverse events associated with TPMT 4900 4600
Mortality prevented per person screened for TPMT 47,600 1600
Life expectancy 5700
Sensitivity of PCR test 4800 4700
Costs of PCR test 700 9800
Costs of myelosuppression 5000 4500
Baseline             4800
*For lower and upper values of model parameters see Table 1.
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country differences are the cost variables, as
other factors, including the prevalence of TPMT
deficiency, may be assumed to be similar across
the mostly Caucasian populations of these coun-
tries. Since expert interviewees estimated a much
lower cost for PCR costs in the UK, using the
low-end UK value yields approximately sixfold
more favorable cost-effectiveness for TPMT gen-
otyping compared with the base value presented
in Table 2. Since hospitalization costs calculated
for myelosuppression were highest in the UK,
this further contributes to the conclusion –
according to base values employed here – that
among the four studies European countries
TPMT genotyping in children with ALL is the
most cost-effective in the UK. In contrast, the
higher PCR costs estimated for Ireland mean
that in this country cost-effectiveness is lower
than in other study countries. We may assume
that in future, due to better availability of TPMT
genotyping services, TPMT genotyping would
become less expensive, further improving its
cost-effectiveness, and minimizing cost-differen-
tials between countries. 
Thiopurine drugs are commonly used for
additional indications other than ALL, most
notably, for treating rheumatoid arthritis (RA),
inflammatory bowl disease (IBD), and other
autoimmune diseases and for immune suppres-
sion following tissue transplants [40] Life-threat-
ening myelosuppression is a common ADR
associated with thiopurine therapy. Estimates for
rates of dangerous myelosuppression appear to
be similar for pediatric ALL and the other indi-
cations (approximately 3% of patients receiving
high-dose thiopurine drugs), and TPMT geno-
typing costs, as well as hospitalization costs used
in the current study are likely in the same
approximate range for the other indications.
Therefore, although further studies may be
required, it appears from the current study that
TPMT genotyping might also show favorable
cost-effectiveness values for the above mentioned
additional indications. 
It remains obvious from this study that there
is a crucial need for more detailed cost-effective-
ness analyses of further examples of the use of
pharmacogenetics in the clinic for reducing the
alarmingly high rates of ADRs [41], which have
been estimated in recent studies to be directly
related to over 6% of hospital admissions in the
UK [42], as well as in Germany [43]. Hopefully,
additional studies yielding data regarding favora-
ble societal cost-effectiveness of PGx testing
would assist in its implementation as an integral
part of pharmacotherapy decision making for
drugs having narrow therapeutic indexes
similarly to thiopurines.
In spite of favorable cost-effectiveness values
for PGx in the clinic, as reported here and in pre-
vious studies [27–29], levels of clinical implemen-
tation of PGx remain low, as concluded by the
recent IPTS study on ‘Pharmacogenetics and
pharmacogenomics: State-of-the-art and poten-
tial socio-economic impacts in the EU’ [102]. As
indicated in the IPTS report, this seems to be
due, in part, to barriers of physician awareness
and education on the potential clinical benefits
of genomics and pharmacogenetics [44–46]. We
hope that the present findings on the evident
cost-effectiveness of TPMT genotyping prior to
the initiation of pharmacotherapy with thiopu-
rine drugs would stimulate further studies on
cost-effectiveness of pharmacogenetics in health-
care, and eventually contribute to its wider
implementation in the clinic.
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